O.P. Purohit

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

J. Lester, David Dodwell, O.P. Purohit et al. · Clinical Cancer Research · 2008 · 189 citations

Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease

J. Vinholes, O.P. Purohit, Mavis Abbey et al. · Annals of Oncology · 1997 · 169 citations

Bone Disease, Bone Health, Orthopaedic Surgery +11

Bone resorption predicts for skeletal complications in metastatic bone disease

Janet E. Brown, C S Thomson, Sue Ellis et al. · British Journal of Cancer · 2003 · 165 citations · Full text

Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease

S. Jagdev, O.P. Purohit, Sarah Heatley et al. · Annals of Oncology · 2001 · 109 citations

Bone Disease, Bone Health, Bone Resorption +7

Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease

Robert E. Coleman, O.P. Purohit, Casilda G. Black et al. · Annals of Oncology · 1999 · 95 citations · Full text

Dose-finding Study, Bone Disease, Bone Health +7